Press Releases

Press Releases

Press Releases

November 27, 2023
RVL Completes Financial Restructuring
Athyrium Provides Capital to Support Long-Term Growth and Exchanges Outstanding Debt into Equity of Certain Reorganized Entities RVL Pharmaceuticals plc Ordinary Shares Expected to be Cancelled in 2024 BRIDGEWATER, N.J., Nov. 27, 2023 (GLOBE NEWSWIRE) --   RVL Pharmaceuticals, Inc.
August 14, 2023
RVL Pharmaceuticals plc Reports Second Quarter 2023 Financial Results; Provides Update on Strategic Business Review
RVL Pharmaceuticals plc (Nasdaq: RVLP) (“RVL” or the “Company”), a specialty pharmaceutical company focused on the commercialization of UPNEEQ® (oxymetazoline hydrochloride ophthalmic solution), 0.1%, for the treatment of acquired blepharoptosis, or low-lying eyelid, in adults, today announced financial results for the three months ended June 30, 2023, and provided an update on its business review.
July 5, 2023
RVL Pharmaceuticals plc Provides Business Update
BRIDGEWATER, N.J., July 05, 2023 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (Nasdaq: RVLP) (“RVL” or the “Company”), a specialty pharmaceutical company organized in Ireland focused on the commercialization of UPNEEQ ® (oxymetazoline hydrochloride ophthalmic solution), 0.1%, for the treatment of
Displaying 1 - 10 of 14